Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Processa Pharmaceuticals, Inc.
Report date April 30, 2026 · Filed May 19, 2026 · Amendment
Section 16 reporting ended · disclosed 2026-05-19. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,481 |
Reported balance
After 2026-04-30 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-04-30 · Purchase · Acquired 1,971 · Balance 7,481 F1: Shares adjusted to correct immaterial errors. |
| Common StockSEC Table I · non-derivative | IndirectBy CorLyst, LLC | 267 |
Reported balance
Holding disclosure · report date 2026-04-30 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 267 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares adjusted to correct immaterial errors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2026 Filed May 1, 2026 20:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,986 | $2.69 | $5,342.34 |
DisclosureSEC source: 0000897069-26-001000 · form4.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,496 Read SEC document |
| April 30, 2026 Filed May 19, 2026 21:17 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,971 | $2.71 | $5,341.41 |
DisclosureSEC source: 0000897069-26-001154 · form4a.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,481 F1 · shares: Shares adjusted to correct immaterial errors. F1 · price: Shares adjusted to correct immaterial errors. F1 · balance_after: Shares adjusted to correct immaterial errors. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:50 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,799 | $2.97 | $5,343.03 |
DisclosureSEC source: 0000897069-26-000904 · form4.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,510 Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:08 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,107 | $2.54 | $5,341.25 |
DisclosureSEC source: 0000897069-26-000743 · form4.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,711 Read SEC document |
| January 01, 2026 Filed Feb 4, 2026 22:04 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock Units · Derivative | 249 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-000218 · form4.xml · derivative · entry 3 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 249 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. Read SEC document |
| January 01, 2026 Filed Feb 4, 2026 22:04 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 249 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-000218 · form4.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:29 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantStock Options (Right to Buy) · Derivative | 288,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000897069-25-001549 · form4.xml · derivative · entry 2 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,000 Underlying: Common Stock · 288,000 shares Expires not disclosed F2 · derivative.exercise_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F2 · derivative.expiration_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:29 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 96,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001549 · form4.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 20:32 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 1,659,185 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001219 · form4.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,672,087 Underlying: Common Stock · 1,659,185 shares Expires not disclosed F1 · shares: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,638,778 shares are subject to stockholder approval of the revised Omnibus Plan. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028. Read SEC document |
| April 01, 2025 Filed Apr 11, 2025 21:17 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 3,311 | $0.41 | $1,364.13 |
DisclosureSEC source: 0000897069-25-000789 · form4.xml · nonDerivative · entry 2 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,626 Read SEC document |
| April 01, 2025 Filed Apr 11, 2025 21:17 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 15,059 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-25-000789 · form4.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| July 10, 2024 Filed Aug 2, 2024 21:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 225 | $1.71 | $384.75 |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · nonDerivative · entry 4 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,878 Read SEC document |
| July 10, 2024 Filed Aug 2, 2024 21:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · nonDerivative · entry 3 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 404 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · derivative · entry 9 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,961 Underlying: Common Stock · 404 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 404 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · derivative · entry 8 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,557 Underlying: Common Stock · 404 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 2,425 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · derivative · entry 7 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,153 Underlying: Common Stock · 2,425 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 3,233 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · derivative · entry 6 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,728 Underlying: Common Stock · 3,233 shares Expires not disclosed F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 368 | $2.79 | $1,026.72 |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · nonDerivative · entry 2 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,459 Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:52 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock Units · Derivative | 1,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-000919 · form4.xml · derivative · entry 4 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,139 Underlying: Common Stock · 1,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:52 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 368 | $2.79 | $1,026.72 |
DisclosureSEC source: 0000897069-24-000919 · form4.xml · nonDerivative · entry 2 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,458 F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:52 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-000919 · form4.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:38 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 48,490 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000320 · doc1.xml · derivative · entry 3 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,475 Underlying: Common Stock · 48,490 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. F3 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:38 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 75,907 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000320 · doc1.xml · derivative · entry 2 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,985 Underlying: Common Stock · 75,907 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. F2 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:38 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 13,851 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000320 · doc1.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,073 Underlying: Common Stock · 13,851 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:55 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 13,850 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018061 · doc1.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,227 Underlying: Common Stock · 13,850 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:25 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 7,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-015305 · doc1.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:41 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 25,611 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013685 · doc1.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,377 Underlying: Common Stock · 25,611 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| April 01, 2022 Filed Apr 11, 2022 21:58 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 247,841 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008369 · doc1.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,766 Underlying: Common Stock · 247,841 shares Expires not disclosed F1 · derivative.exercise_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F1 · derivative.expiration_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F2 · balance_after: The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:52 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,715 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007998 · doc1.xml · derivative · entry 2 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,781 Underlying: Common Stock · 10,715 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:32 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000304 · doc1.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,722 Underlying: Common Stock · 6,722 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| December 31, 2021 Filed Jan 6, 2022 22:28 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000779 · doc1.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,780 Underlying: Common Stock · 6,722 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| November 01, 2021 Filed Apr 4, 2022 21:52 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 4,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007998 · doc1.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,066 Underlying: Common Stock · 4,286 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:49 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-017833 · doc1.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,024 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| September 30, 2021 Filed Jan 6, 2022 20:58 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000710 · doc1.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,058 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:40 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 7,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-014751 · doc1.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,418 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:42 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 1,907 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013191 · doc1.xml · derivative · entry 3 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,034 Underlying: Common Stock · 10,034 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:42 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 12,858 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013191 · doc1.xml · derivative · entry 2 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,858 Underlying: Common Stock · 12,858 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Units vest upon achievement of certain performance goals. F2 · derivative.expiration_date: The Restricted Stock Units vest upon achievement of certain performance goals. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:42 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013191 · doc1.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,572 Underlying: Common Stock · 8,572 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units vest in two equal installments beginning July 1, 2022. F1 · derivative.expiration_date: The restricted stock units vest in two equal installments beginning July 1, 2022. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:13 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,127 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011986 · doc1.xml · derivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,127 Underlying: Common Stock · 8,127 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.